Open AccessWhole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study
Author(s) -
Helen Cox,
Galo A. Goig,
Zubeida Salaam-Dreyer,
Anzaan Dippenaar,
Anja Reuter,
Erika Mohr,
Johnny Daniels,
Patrick Cudahy,
Mark P. Nicol,
Sònia Borrell,
Miriam Reinhard,
Anna Doetsch,
Christian Beisel,
Sébastien Gagneux,
Robin M. Warren,
Jennifer Furin
Publication year - 2022
Publication title -
journal of clinical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.349
H-Index - 255
eISSN - 1070-633X
pISSN - 0095-1137
DOI - 10.1128/jcm.02362-21
Subject(s) - regimen , medicine , retrospective cohort study , cohort , drug resistance , extensively drug resistant tuberculosis , tuberculosis , cohort study , pediatrics , intensive care medicine , mycobacterium tuberculosis , biology , pathology , genetics
Treatment of multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB), although improved in recent years with shorter, more tolerable regimens, remains largely standardized and based on limited drug susceptibility testing (DST). More individualized treatment with expanded DST access is likely to improve patient outcomes.